Toboroz
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Joaquin Mateo Valderrama (principal investigator)
Toboroz
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270· 1. fázis· GlaxoSmithKline· Forrás
Contact: Guzman Alonso Casal (principal investigator)
Toboroz
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Victoria Sanchez Perez (principal investigator)
Toboroz
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709· 2. fázis· GlaxoSmithKline· Forrás
Contact: Merce Boada (principal investigator)
Toboroz
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· 3. fázis· GlaxoSmithKline· Forrás
Contact: Edurne Arriola Aperribay (principal investigator)
Toboroz
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Tatiana Hernandez (principal investigator)
Toboroz
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Elena Elez (principal investigator)
Toboroz
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782· 2. fázis· GlaxoSmithKline· Forrás
Contact: David Paez Lopez-Bravo (principal investigator)
Fut, nem toboroz
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847· 1/2. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606· 3. fázis· GlaxoSmithKline· Forrás
Contact: Alfredo Guillen Del Castillo (principal investigator)
Fut, nem toboroz
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234· 1. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· 2. fázis· GlaxoSmithKline· Forrás
Contact: Montserrat Garcia Retortillo (principal investigator)
Fut, nem toboroz
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051· 1. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· 1. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· 1. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· 3. fázis· ViiV Healthcare· Forrás